U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula 2C12H19NO2.H2O4S
Molecular Weight 516.648
Optical Activity ( + / - )
Defined Stereocenters 0 / 2
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BAMETHAN SULFATE

SMILES

OS(O)(=O)=O.CCCCNCC(O)C1=CC=C(O)C=C1.CCCCNCC(O)C2=CC=C(O)C=C2

InChI

InChIKey=PARMADWNFXEEFC-UHFFFAOYSA-N
InChI=1S/2C12H19NO2.H2O4S/c2*1-2-3-8-13-9-12(15)10-4-6-11(14)7-5-10;1-5(2,3)4/h2*4-7,12-15H,2-3,8-9H2,1H3;(H2,1,2,3,4)

HIDE SMILES / InChI

Molecular Formula C12H19NO2
Molecular Weight 209.2848
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Molecular Formula H2O4S
Molecular Weight 98.078
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Bamethan (butyl-sympatol or vasculat) is an adrenaline derivative developed by C. H. Boehringer Sohn. Bamethan shows a depressor action on peripheral blood vessels as a result of the peripheral vasodilating action caused by stimulation of adrenergic beta-receptor. Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
VASCULAT

Approved Use

Bamethan has been used abroad in the treatment of certain peripheral vascular and circulatory disturbances, such as vasospastic conditions, arteriosclerotic peripheral vascular disease, Raynaud's syndrome, occlusive vascular disease of the legs, the post-thrombotic syndrome, degenerative muscular disorders, and other conditions involving peripheral vascular insuffciency.
PubMed

PubMed

TitleDatePubMed
The effect of bamethan on cardiovascular response.
1966 Jan-Feb
Development and validation of a liquid chromatography/tandem mass spectrometry (LC/MS/MS) method for the determination of ribavirin in human plasma and serum.
2002 Jun 20

Sample Use Guides

75-100 mg
Route of Administration: Oral
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:07:30 GMT 2023
Edited
by admin
on Fri Dec 15 15:07:30 GMT 2023
Record UNII
W2L3E1W827
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BAMETHAN SULFATE
MART.   MI   USAN   WHO-DD  
USAN  
Official Name English
.ALPHA.-((BUTYLAMINO)METHYL)-P-HYDROXYBENZYL ALCOHOL SULFATE (2:1) (SALT)
Common Name English
VASCULAT
Brand Name English
BAMETHAN HEMISULFATE SALT
Common Name English
BAMETHAN SULFATE [MART.]
Common Name English
BUTYLNORSYMPATOL
Brand Name English
BAMETHAN HEMISULFATE
Common Name English
BASCURAT
Brand Name English
VASCULIT
Brand Name English
BAMETHAN SULFATE [USAN]
Common Name English
ECLERN
Brand Name English
BAMETHAN SULFATE [MI]
Common Name English
BAMETHAN SULFATE [JAN]
Common Name English
BAMETHAN SULPHATE
Common Name English
ROTESAR
Brand Name English
.ALPHA.-((BUTYLAMINO)METHYL)-P-HYDROXYBENZYL ALCOHOL SULPHATE (2:1) (SALT)
Common Name English
GARMIAN
Brand Name English
BENZENEMETHANOL, .ALPHA.-((BUTYLAMINO)METHYL)-4-HYDROXY-, SULFATE (2:1) (SALT)
Common Name English
BENZENEMETHANOL, .ALPHA.-((BUTYLAMINO)METHYL)-4-HYDROXY-, SULPHATE (2:1) (SALT)
Common Name English
Bamethan sulfate [WHO-DD]
Common Name English
BUPATOL
Brand Name English
PERIPHETOL
Brand Name English
BUTEDRIN
Brand Name English
Classification Tree Code System Code
NCI_THESAURUS C48149
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID90972621
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
MERCK INDEX
m2217
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY Merck Index
CAS
5716-20-1
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
ChEMBL
CHEMBL1987462
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
SMS_ID
100000084970
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
FDA UNII
W2L3E1W827
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
PUBCHEM
21955
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
ECHA (EC/EINECS)
227-214-9
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
DRUG BANK
DBSALT002804
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
EVMPD
SUB00660MIG
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
NCI_THESAURUS
C76117
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
RXCUI
102345
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY RxNorm
MESH
C084810
Created by admin on Fri Dec 15 15:07:30 GMT 2023 , Edited by admin on Fri Dec 15 15:07:30 GMT 2023
PRIMARY
Related Record Type Details
ENANTIOMER -> RACEMATE
ENANTIOMER -> RACEMATE
Related Record Type Details
ACTIVE MOIETY